• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Focalin (dexmethylphenidate hydrochloride) and Focalin XR (dexmethylphenidate hydrochloride) Extended-Release Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – May 2012

 

Summary View

 

CONTRAINDICATIONS

Hypersensitivity to Methylphenidate
  • Focalin is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product. Hypersensitivity reactions, including angioedema and anaphylactic reactions, have been observed in patients treated with methylphenidate

ADVERSE REACTIONS 

Adverse Events from Postmarketing Experience
  • new section added

MEDICATION GUIDE

Other serious side effects include:
  • Serious allergic reactions (symptoms can be difficulty breathing, swelling of the face, neck and throat, rashes and hives, fever)
  • slowing of growth (height and weight) in children
  • seizures, mainly in patients with a history of seizures
  • eyesight changes or blurred vision